Abstract：With the continuous deepening of the research on tumor pathogenesis, more and more innovative oncology drugs have been approved on the market, mainly including targeted antitumor drugs and immune checkpoint inhibitors. These new antitumor drugs have the advantages of high specificity, precise targeting, good efficacy, and low toxicity to greatly improve the patient quality of life and prognosis. However, because of the different types and monitoring methods of their adverse drug reactions from those of the traditional chemotherapy ones, the research on these drugs from aspects of prediction of adverse drug reactions, the relationship between adverse drug reactions and gene polymorphisms, and the therapeutic drug monito- ring are still necessary to be further researched.
姜帅， 蔡晧东， 董梅. 应重视对新型抗肿瘤药物不良反应的监测[J]. 药物不良反应杂志, 2020, 22(4): 217-220.
Jiang Shuai, Cai Haodong, Dong Mei. Attention should be paid to monitoring of adverse reactions to new antitumor drugs. Adverse Drug Reactions Journal, 2020, 22(4): 217-220.
